Know Cancer

forgot password

A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Phase 1
18 Years
Not Enrolling
Leukemia, Lymphocytic, Leukemia, Acute Lymphocytic Leukemia

Thank you

Trial Information

A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Inclusion Criteria:

3.1.1 Age Patients must be >= 18 years old at the time of study entry.

3.1.2 Diagnosis Histologic Verification Patients must have had histologic verification of
B-lineage ALL with bone marrow relapse or refractory disease that is unresponsive to
traditional chemotherapy. For patients WITHOUT prior allogeneic BMT:

1. Second or subsequent bone marrow relapse

2. Primary refractory marrow disease

3. M3 marrow (>25% blasts) or >25% leukemic blasts in peripheral blood For patients WITH prior allogeneic BMT:

1. First or subsequent bone marrow relapse post-BMT

2. M3 marrow or M2 (>5 % and <25% blasts) if cytogenetic or VNTR confirmation

3.1.3 Confirmation of antibody reactivity Patient's leukemic blasts (peripheral
blood or marrow) must be documented to bind mAb 216 in vitro (Teng lab)
Patient's RBC documented to NOT express fetal "i" antigen and RBC shown to NOT bind mAb
216 in vitro (Teng lab)

3.1.4 Patient Must Not Be Eligible For Therapies of Higher Priority

3.1.5 Performance Level (See Appendix I) Karnofsky >= 50%

3.1.6 Life Expectancy Must be at least 8 weeks.

3.1.7 Prior Therapy Patients must have fully recovered from the acute toxic effects of all
prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

1. Myelosuppressive chemotherapy: Must not have received within one week of entry onto
this study.

2. Biologic, including monoclonal antibodies: At least 2 weeks since the completion of
therapy with a biologic agent including monoclonal antibodies.

3. Hydroxyurea can be used up to 72 hours before study entry

3.1.8 Organ Function Requirements Bone Marrow Function: No hematologic criteria for WBC, Hgb or platelets Patients with thrombocytopenia should be responsive to platelet transfusions and
must not have uncontrolled bleeding. Adequate Renal Function Defined As:

- A serum creatinine that is less than or equal to 2 x normal for age Adequate Liver Function Defined As:

- Total bilirubin <= 2 x upper limit of normal (ULN) for age, and

- SGPT (ALT) <= 5 x upper limit of normal (ULN) for age Adequate Cardiac Function Defined As:

- Shortening fraction of >= 27% by echocardiogram, or

- Ejection fraction of >= 50% by gated radionuclide study.

3.1.9 Regulatory All patients must sign a written informed consent. All institutional (IRB)
and FDA requirements for human studies must be met.

Exclusion Criteria:

3.2.1 CNS 3 or refractory CNS leukemia

3.2.2 Isolated extramedullary relapse

3.2.3 Uncontrolled infection

3.2.4 Lack of mAb 216 binding to patient's leukemic blasts in vitro

3.2.5 Binding of mAb 216 to the "i" antigen on patient's erythrocytes

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

In this phase I study the endpoint is the determination of the maximum tolerable dose without toxicity.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Nelson N Teng

Investigator Role:


Investigator Affiliation:

Stanford University


United States: Institutional Review Board

Study ID:




Start Date:

May 2006

Completion Date:

July 2009

Related Keywords:

  • Leukemia, Lymphocytic
  • Leukemia
  • Acute Lymphocytic Leukemia
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma



Stanford University School of Medicine Stanford, California  94305-5317